• Mashup Score: 2
    Longitudinal Serum Proteomics Characterization of CD19-CAR-T Cell Therapy for B-Cell Malignancies - 9 month(s) ago

    Chimeric antigen receptor (CAR)-modified T cells have demonstrated remarkable efficacy in treating B-cell leukemia. However, treated patients may potentially develop side effects, such as cytokine release syndrome (CRS), the mechanisms of which remain unclear. Here, we collected 43 serum samples from eight patients with B-cell acute lymphoblastic leukemia (B-ALL) before and five time points after CD19-specific CAR-T cell treatment. Using TMTpro 16-plex-based quantitative proteomics, we quantified 1151 proteins and profiled the longitudinal proteomes analysis of each patient. Seven days after therapy, we found the most dysregulated inflammatory proteins. Lipid metabolism proteins, including APOA1, decreased after therapy, reached their minimum after 7 days, and then gradually recovered. Hence, APOA1 has been selected as a potential biomarker of the CRS disease progression. Furthermore, we identified CD163 as a potential biomarker of CRS severity. These two biomarkers were successfully v

    Source: pubs.acs.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CARTTherapy
      CARTTherapy

      Longitudinal Serum Proteomics Characterization of CD19-CAR-T Cell Therapy for B-Cell https://t.co/BFxU4gAtC4 @CART_Therapy #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CARTTherapy Interesting data APOA1 and CD163

  • Mashup Score: 0
    Single-cell RNA analysis reveals cell-intrinsic functions of CAR-T cells correlating with response in a phase II study of lymphoma patients - 9 month(s) ago

    Abstract. Purpose: Although CD19 CAR-T cell therapy has shown remarkable success in B cell malignancies, a substantial fraction of patients does not obtain a long-term clinical response. This could be influenced by the quality of the individual CAR-T infusion product. To shed some light on this, clinical outcome was correlated to characteristics of CAR-T cell infusion products. Patients and Methods: In this phase II study patients with B cell lymphoma (n=23) or leukemia (n=1) received one or two infusions of third generation CD19-directed CAR-T cells (2×108/m2). The clinical trial was registered at clinicaltrials.gov: NCT03068416. We investigated the transcriptional profile of individual third generation CD19 CAR-T infusion products using targeted single-cell RNA sequencing and multicolor flow cytometry. Results: Two CAR-T infusions were not better than one in the settings used in this study. As for the CAR-T infusion products we found that effector-like CD8+CAR-T cells with a high pol

    Source: aacrjournals.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CARTTherapy
      CARTTherapy

      Single-cell RNA analysis reveals cell-intrinsic functions of CAR-T cells correlating with response in a phase II study of lymphoma patients https://t.co/clWgr5NSKI @CART_Therapy #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy

  • Mashup Score: 1
    Meet ‘Fanzor,’ a cousin of CRISPR and Feng Zhang’s new gene editing tool - 10 month(s) ago

    Microbes have lost their monopoly as the sole source of new enzymes that can be easily programmed to make precise edits to the genome. Two independent teams, both led by scientists from the Massachusetts Institute of Technology, unveiled new gene editing tools on Wednesday based on proteins called

    Source: Endpoints News
    Categories: Healthcare Professionals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of IrmaRaste
      IrmaRaste

      Meet ‘Fanzor,’ a cousin of #CRISPR and Feng Zhang’s new #gene editing tool by @endpts @eViRaHealth @EvanKirstel #geneediting #pharma #biotech #biopharma #pharmaceuticals #pharmaceuticalindustry #lifesciences #research https://t.co/i31m2cbKOV https://t.co/8AQo2K63LY

  • Mashup Score: 0
    The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies - 11 month(s) ago

    Section snippetsKey points•Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies have led to significant advancements in the management of relapsed/refractory blood cancers with several FDA approved products for multiple myeloma, non-Hodgkin lymphoma and B-cell lymphoblastic leukemia.•In the absence of head-to-head comparisons of CAR T-cell therapy versus bispecific antibodies,…

    Source: www.sciencedirect.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CARTTherapy
      CARTTherapy

      The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bis... https://t.co/pazRLv2zXB #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CARTTherapy

  • Mashup Score: 0
    The importance of molecular endocrinology: A conversation with Mitchell A. Lazar, MD, PhD - 11 month(s) ago

    Mitchell A. Lazar, MD, PhD, has always been interested in organic chemistry, biochemistry and mental illness, which led him to delve into research on the regulation of gene expression in response to hormones, metabolites and drugs.“I love science because its goal is to discover and understand natural phenomena, finding laws and mechanisms underlying all aspects of the world that we

    Source: www.healio.com
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of EndocrineToday
      EndocrineToday

      Fred Conrad Koch Lifetime Achievement Award recipient Mitchell A. Lazar, MD, PhD, spoke with Healio about how he got into #molecular #endocrinology, the future of #gene expression and his research interests. @TheEndoSociety #ENDO2023 @PennMedicine https://t.co/n8OkhqU8Se

Load More